Zhejiang Sunflower Light Energy (300111) - Total Assets
Based on the latest financial reports, Zhejiang Sunflower Light Energy (300111) holds total assets worth CN¥968.31 Million CNY (≈ $141.69 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Zhejiang Sunflower Light Energy - Total Assets Trend (2007–2025)
This chart illustrates how Zhejiang Sunflower Light Energy's total assets have evolved over time, based on quarterly financial data. Also see 300111 stock market capitalisation for the company's overall valuation and market capitalisation.
Zhejiang Sunflower Light Energy - Asset Composition Analysis
Current Asset Composition (December 2025)
Zhejiang Sunflower Light Energy's total assets of CN¥968.31 Million consist of 80.1% current assets and 19.9% non-current assets. Review Zhejiang Sunflower Light Energy total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 51.3% |
| Accounts Receivable | CN¥46.41 Million | 4.7% |
| Inventory | CN¥170.58 Million | 17.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥57.53 Million | 5.9% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2007–2025)
This chart illustrates how Zhejiang Sunflower Light Energy's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See current stock price of Zhejiang Sunflower Light Energy for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zhejiang Sunflower Light Energy's current assets represent 80.1% of total assets in 2025, an increase from 77.7% in 2007.
- Cash Position: Cash and equivalents constituted 51.3% of total assets in 2025, up from 7.1% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 3.0% in 2007.
- Asset Diversification: The largest asset category is inventory at 17.3% of total assets.
Zhejiang Sunflower Light Energy Competitors by Total Assets
Key competitors of Zhejiang Sunflower Light Energy based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Yunnan Baiyao Group Co Ltd
SHE:000538
|
China | CN¥53.34 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Harbin Gloria Pharmaceuticals
SHE:002437
|
China | CN¥3.14 Billion |
|
Jiuzhitang Co Ltd
SHE:000989
|
China | CN¥5.73 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
Zhejiang Sunflower Light Energy - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.71 | 6.17 | 2.88 |
| Quick Ratio | 5.20 | 5.04 | 2.19 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥657.01 Million | CN¥649.50 Million | CN¥197.11 Million |
Zhejiang Sunflower Light Energy - Advanced Valuation Insights
This section examines the relationship between Zhejiang Sunflower Light Energy's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.72 |
| Latest Market Cap to Assets Ratio | 0.57 |
| Asset Growth Rate (YoY) | -1.5% |
| Total Assets | CN¥984.18 Million |
| Market Capitalization | $565.08 Million USD |
Valuation Analysis
Below Book Valuation: The market values Zhejiang Sunflower Light Energy's assets below their book value (0.57x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Zhejiang Sunflower Light Energy's assets decreased by 1.5% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Zhejiang Sunflower Light Energy (2007–2025)
The table below shows the annual total assets of Zhejiang Sunflower Light Energy from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥984.18 Million ≈ $144.02 Million |
-1.49% |
| 2024-12-31 | CN¥999.12 Million ≈ $146.20 Million |
-19.56% |
| 2023-12-31 | CN¥1.24 Billion ≈ $181.75 Million |
+101.55% |
| 2022-12-31 | CN¥616.25 Million ≈ $90.18 Million |
-2.44% |
| 2021-12-31 | CN¥631.63 Million ≈ $92.43 Million |
+11.90% |
| 2020-12-31 | CN¥564.44 Million ≈ $82.60 Million |
-18.67% |
| 2019-12-31 | CN¥694.03 Million ≈ $101.56 Million |
-52.35% |
| 2018-12-31 | CN¥1.46 Billion ≈ $213.11 Million |
-45.97% |
| 2017-12-31 | CN¥2.70 Billion ≈ $394.46 Million |
-3.86% |
| 2016-12-31 | CN¥2.80 Billion ≈ $410.28 Million |
-8.93% |
| 2015-12-31 | CN¥3.08 Billion ≈ $450.52 Million |
-2.38% |
| 2014-12-31 | CN¥3.15 Billion ≈ $461.51 Million |
+9.74% |
| 2013-12-31 | CN¥2.87 Billion ≈ $420.54 Million |
-5.39% |
| 2012-12-31 | CN¥3.04 Billion ≈ $444.47 Million |
-14.43% |
| 2011-12-31 | CN¥3.55 Billion ≈ $519.44 Million |
+26.27% |
| 2010-12-31 | CN¥2.81 Billion ≈ $411.37 Million |
+46.80% |
| 2009-12-31 | CN¥1.92 Billion ≈ $280.23 Million |
+19.34% |
| 2008-12-31 | CN¥1.60 Billion ≈ $234.81 Million |
+189.05% |
| 2007-12-31 | CN¥555.16 Million ≈ $81.24 Million |
-- |
About Zhejiang Sunflower Light Energy
Zhejiang Sunflower Great Health Co., Ltd. engages in the research, development, production, and sale of anti-infectious, cardiovascular, digestive system and other drugs in China and internationally. It offers clarithromycin API and tablets, anti-infective drugs used for nasopharyngeal infection, lower respiratory tract infection, skin and soft tissue infection, acute otitis media, Mycoplasma pne… Read more